Recurrent GBM

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

SonALAsense
SonALAsenseCA - Oakland
1 program
1
SONALA-001Phase 1/21 trial
Active Trials
NCT05370508TerminatedEst. Jul 2024
Celldex Therapeutics
1 program
rindopepimutN/A1 trial
Active Trials
NCT03068650No Longer Available

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
SonALAsenseSONALA-001

Clinical Trials (2)

NCT05370508SonALAsenseSONALA-001

A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

Start: Feb 2023Est. completion: Jul 2024
Phase 1/2Terminated
NCT03068650Celldex Therapeuticsrindopepimut

Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut

N/ANo Longer Available

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space